Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Liabilities and Shareholders Equity (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Liabilities and Shareholders Equity for 14 consecutive years, with $8.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 32.08% year-over-year to $8.6 million, compared with a TTM value of $34.6 million through Dec 2025, up 56.23%, and an annual FY2025 reading of $10.8 million, up 100.85% over the prior year.
  • Liabilities and Shareholders Equity was $8.6 million for Q4 2025 at Neuroone Medical Technologies, down from $10.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $17.2 million in Q4 2021 and bottomed at $4.5 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $8.9 million, with a median of $8.3 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity tumbled 50.24% in 2023, then skyrocketed 120.24% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $17.2 million in 2021, then crashed by 43.78% to $9.7 million in 2022, then crashed by 39.73% to $5.8 million in 2023, then increased by 11.54% to $6.5 million in 2024, then skyrocketed by 32.08% to $8.6 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for NMTC at $8.6 million in Q4 2025, $10.8 million in Q3 2025, and $10.8 million in Q2 2025.